Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com.
Looking for a particular Precision BioSciences, Inc. employee's phone or email?
The Precision BioSciences, Inc. annual revenue was $75.1 million in 2026.
Michael Amoroso is the President and CEO of Precision BioSciences, Inc..
114 people are employed at Precision BioSciences, Inc..
Precision BioSciences, Inc. is based in Durham, North Carolina.
The NAICS codes for Precision BioSciences, Inc. are [54, 541, 32541, 325, 32, 3254].
The SIC codes for Precision BioSciences, Inc. are [873, 87].